Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque

Circulation. 1999 Jan 26;99(3):420-6. doi: 10.1161/01.cir.99.3.420.

Abstract

Background: The accumulation of macrophage-derived foam cells in atherosclerotic lesions correlates with increased local release of matrix-degrading metalloproteinases (MMPs) and a thin fibrous cap. The activity of these enzymes is controlled by specific tissue inhibitors of metalloproteinases (TIMPs).

Methods and results: Because oxidized low-density lipoprotein (OxLDL) modulates gene expression, we investigated the effect of these particles on the levels of MMP-1, MMP-3, MMP-9, TIMP-1, and TIMP-2 in the culture media of human monocyte-derived macrophages. OxLDL but not native LDL or high-density lipoprotein reduced the level of TIMP-1 in a dose-dependent manner with maximal effect (60% of control) at approximately 100 microg protein/mL. In addition, Northern blotting revealed marked reduction in the abundance of TIMP-1 mRNA in OxLDL-treated cells. Evaluation of the effect of oxysterol components of OxLDL on TIMP-1 production revealed that 25-hydroxycholesterol (1 microg/mL) was the most potent inhibitor ( approximately 30% of control). Such inhibition was partially mediated by interleukin (IL)-8. Indeed, IL-8 (2.5 ng/mL) induced maximal inhibition of TIMP-1 accumulation (30% of control) in 4 of 6 cell preparations. In addition, the inhibitory effect of OxLDL-treated cells in the presence of an anti-IL-8 neutralizing antibody was partially reversed.

Conclusions: Immunohistochemical analyses of human atherosclerotic plaques revealed the expression of TIMP-1 in some but not all macrophage-rich and IL-8-rich areas. Therefore, IL-8 may play a potential atherogenic role by inhibiting local TIMP-1 expression, thereby leading to an imbalance between MMPs and TIMPs at focal sites in the atherosclerotic plaque.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Antigens, CD / analysis
  • Antigens, CD / immunology
  • Antigens, Differentiation, Myelomonocytic / analysis
  • Antigens, Differentiation, Myelomonocytic / immunology
  • Arteriosclerosis / metabolism*
  • Arteriosclerosis / pathology
  • Carotid Arteries / chemistry
  • Carotid Arteries / enzymology
  • Carotid Arteries / pathology
  • Cells, Cultured
  • Cholesterol, LDL / metabolism
  • Cholesterol, LDL / pharmacology
  • Collagenases / analysis
  • Collagenases / immunology
  • Collagenases / metabolism*
  • Gene Expression Regulation, Enzymologic
  • Humans
  • Interleukin-8 / analysis
  • Interleukin-8 / immunology
  • Interleukin-8 / metabolism*
  • Macrophages / chemistry
  • Macrophages / drug effects
  • Macrophages / enzymology*
  • Matrix Metalloproteinase 1
  • Matrix Metalloproteinase 3 / analysis
  • Matrix Metalloproteinase 3 / immunology
  • Matrix Metalloproteinase 3 / metabolism
  • Matrix Metalloproteinase 9
  • Monocytes / chemistry
  • Monocytes / drug effects
  • Monocytes / enzymology
  • Oxidation-Reduction
  • Tissue Inhibitor of Metalloproteinase-1 / genetics*
  • Tissue Inhibitor of Metalloproteinase-1 / immunology
  • Tissue Inhibitor of Metalloproteinase-2 / analysis
  • Tissue Inhibitor of Metalloproteinase-2 / genetics
  • Tissue Inhibitor of Metalloproteinase-2 / immunology

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD68 antigen, human
  • Cholesterol, LDL
  • Interleukin-8
  • Tissue Inhibitor of Metalloproteinase-1
  • Tissue Inhibitor of Metalloproteinase-2
  • Collagenases
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinase 1